QIAN DU

Senior Manager at Aitia

Qian Du has a diverse work experience spanning several companies and institutions. Starting in 2011, Qian completed a summer research internship at the Chinese Academy of Sciences. In 2013, Qian worked as a lab technician at Tsinghua University for a limited period. Qian then pursued a graduate research assistant role at the University of Nebraska-Lincoln, beginning in 2014 and ending in 2019. During this time, Qian also participated in a fellowship program at Insight Data Science for a short period in 2019. Finally, Qian joined Aitia in 2020, initially as a research scientist and later progressed to the role of senior research scientist. Currently, Qian holds the position of senior manager at Aitia.

Qian Du has a strong educational background in the field of bioinformatics. From 2014 to 2019, Qian attended the University of Nebraska-Lincoln and obtained a Doctor of Philosophy (PhD) degree in Bioinformatics. During the same period, Qian also pursued a Master of Science (M.S.) degree in Statistics from the same university, completing it from 2015 to 2016. Prior to this, Qian earned a Bachelor of Science (B.S.) degree in Developmental Biology from Shandong University, graduating from 2008 to 2012.

In addition to formal education, Qian Du has also pursued additional certifications to enhance their skill set. In April 2020, Qian completed the Deep Learning Specialization from Coursera. In January 2019, Qian obtained the SAS Certified Advanced Programmer for SAS 9 certification from SAS. Furthermore, in June 2017, Qian completed the Python for Everybody Specialization, also from Coursera.

Location

Medford, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Aitia

1 followers

Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.


Industries

Employees

51-200

Links